• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较他卡西醇和罗氟司特局部治疗药物在轻中度斑块状银屑病治疗中的安全性和疗效。

A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild-to-moderate plaque psoriasis.

机构信息

Dermatology Clinical Trials Unit, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Rowan-Virtua School of Osteopathic Medicine, Stratford, New Jersey, USA.

出版信息

Skin Res Technol. 2024 Sep;30(9):e70041. doi: 10.1111/srt.70041.

DOI:10.1111/srt.70041
PMID:39206797
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11359094/
Abstract

INTRODUCTION

Psoriasis is an immune-mediated inflammatory skin disease. First-line topical treatments include steroids, calcineurin inhibitors, vitamin D analogs, and anthralin. Recently, novel topical therapeutics like tapinarof and roflumilast have emerged with unique anti-inflammatory mechanisms and promising efficacy profiles.

MATERIALS AND METHODS

This review utilized PubMed, SCOPUS, and Web of Science databases to identify recent studies on tapinarof and roflumilast. Criteria focused on efficacy, safety profiles, and therapeutic roles in psoriasis treatment.

RESULTS

Four primary literature articles were identified for tapinarof and five for roflumilast. Both drugs demonstrated strong efficacy with minimal adverse events in treating mild-to-moderate plaque psoriasis. Tapinarof showed more frequent but mild adverse effects, while roflumilast had less frequent but more severe side effects.

DISCUSSION

Tapinarof and roflumilast offer once-daily dosing and successful treatment in restricted areas, potentially enhancing patient adherence. Cost remains a limiting factor, necessitating future comparative studies to evaluate the efficacy, safety, and cost-effectiveness between the two drugs.

CONCLUSION

Tapinarof and roflumilast present promising topical treatments for psoriasis, showing efficacy and manageable safety profiles. Further research is crucial to fully elucidate their comparative benefits and drawbacks in clinical practice.

摘要

简介

银屑病是一种免疫介导的炎症性皮肤病。一线局部治疗包括皮质类固醇、钙调磷酸酶抑制剂、维生素 D 类似物和蒽林。最近,新型局部治疗药物如他卡西醇和罗氟司特具有独特的抗炎机制和有前景的疗效特征。

材料和方法

本综述利用 PubMed、SCOPUS 和 Web of Science 数据库,确定了关于他卡西醇和罗氟司特的最新研究。标准侧重于疗效、安全性概况以及在银屑病治疗中的治疗作用。

结果

确定了 4 篇关于他卡西醇的主要文献和 5 篇关于罗氟司特的文献。这两种药物在治疗轻度至中度斑块状银屑病方面均显示出较强的疗效,且不良反应最小。他卡西醇显示出更频繁但较轻的不良反应,而罗氟司特则具有较少但更严重的副作用。

讨论

他卡西醇和罗氟司特提供每日一次的给药方案,并且可以在受限区域成功治疗,这可能会提高患者的依从性。成本仍然是一个限制因素,因此需要未来进行比较研究,以评估这两种药物在疗效、安全性和成本效益方面的差异。

结论

他卡西醇和罗氟司特为银屑病提供了有前景的局部治疗方法,显示出疗效和可管理的安全性特征。进一步的研究对于充分阐明它们在临床实践中的比较优势和劣势至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1381/11359094/8b0b941ed49e/SRT-30-e70041-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1381/11359094/10592d5bcf4e/SRT-30-e70041-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1381/11359094/8b0b941ed49e/SRT-30-e70041-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1381/11359094/10592d5bcf4e/SRT-30-e70041-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1381/11359094/8b0b941ed49e/SRT-30-e70041-g001.jpg

相似文献

1
A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild-to-moderate plaque psoriasis.比较他卡西醇和罗氟司特局部治疗药物在轻中度斑块状银屑病治疗中的安全性和疗效。
Skin Res Technol. 2024 Sep;30(9):e70041. doi: 10.1111/srt.70041.
2
An update on topical therapies for psoriasis.银屑病局部治疗的最新进展。
Curr Opin Rheumatol. 2024 Jul 1;36(4):289-294. doi: 10.1097/BOR.0000000000001018. Epub 2024 Apr 23.
3
Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.外用罗氟司特治疗银屑病的疗效和安全性:一项随机对照试验的系统评价和荟萃分析。
Clin Drug Investig. 2024 Sep;44(9):655-665. doi: 10.1007/s40261-024-01368-w. Epub 2024 Aug 22.
4
A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test.一项评估磷酸二酯酶抑制剂外用治疗寻常型银屑病对皮肤浸润厚度的影响和耐受性的 I 期随机试验,采用改良的银屑病斑块试验。
Br J Dermatol. 2016 Sep;175(3):479-86. doi: 10.1111/bjd.14634. Epub 2016 Aug 8.
5
Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.罗氟司特乳膏改善斑块状银屑病的体征和症状:一项 1/2a 期随机对照研究的结果。
J Drugs Dermatol. 2020 Aug 1;19(8):734-740. doi: 10.36849/JDD.2020.5370.
6
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.罗氟司特乳膏与赋形剂乳膏治疗慢性斑块状银屑病的效果:DERMIS-1 和 DERMIS-2 随机临床试验。
JAMA. 2022 Sep 20;328(11):1073-1084. doi: 10.1001/jama.2022.15632.
7
Topical roflumilast (Zoryve) for plaque psoriasis.用于斑块状银屑病的外用罗氟司特(Zoryve)
Med Lett Drugs Ther. 2023 Jan 23;65(1668):10-12. doi: 10.58347/tml.2023.1668b.
8
Roflumilast cream (Zoryve) for atopic dermatitis.用于特应性皮炎的罗氟司特乳膏(Zoryve)。
Med Lett Drugs Ther. 2024 Sep 16;66(1711):150-151. doi: 10.58347/tml.2024.1711b.
9
New Topical Therapies for Psoriasis.治疗银屑病的新型局部治疗药物。
Am J Clin Dermatol. 2022 Jan;23(1):13-24. doi: 10.1007/s40257-021-00649-w. Epub 2021 Oct 27.
10
Trial of Roflumilast Cream for Chronic Plaque Psoriasis.罗氟司特乳膏治疗慢性斑块状银屑病的试验。
N Engl J Med. 2020 Jul 16;383(3):229-239. doi: 10.1056/NEJMoa2000073.

引用本文的文献

1
Tapinarof Nanogels as a Promising Therapeutic Approach.他扎罗汀纳米凝胶作为一种有前景的治疗方法。
Pharmaceutics. 2025 Jun 1;17(6):731. doi: 10.3390/pharmaceutics17060731.
2
Therapeutic Advancements in Psoriasis and Psoriatic Arthritis.银屑病和银屑病关节炎的治疗进展
J Clin Med. 2025 Feb 16;14(4):1312. doi: 10.3390/jcm14041312.

本文引用的文献

1
Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis.罗氟司特 0.3% 乳膏:用于治疗慢性斑块状银屑病的磷酸二酯酶 4 抑制剂。
Am J Ther. 2023;30(6):e535-e542. doi: 10.1097/MJT.0000000000001678.
2
Noncorticosteroid Topical Therapies for the Treatment of Plaque Psoriasis: A Narrative Review.用于治疗斑块状银屑病的非皮质类固醇外用疗法:一项叙述性综述
J Pharm Technol. 2023 Oct;39(5):247-255. doi: 10.1177/87551225231193057. Epub 2023 Aug 19.
3
Topical roflumilast for the treatment of psoriasis.外用罗氟司特治疗银屑病。
Expert Rev Clin Immunol. 2023 Jul-Dec;19(9):1053-1062. doi: 10.1080/1744666X.2023.2219897. Epub 2023 May 30.
4
Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial.1% 他扎罗汀乳膏每日一次治疗斑块状银屑病:PSOARING 3试验的患者报告结局
J Am Acad Dermatol. 2023 Nov;89(5):936-944. doi: 10.1016/j.jaad.2023.04.061. Epub 2023 May 10.
5
A Review of Topical Tapinarof for the Treatment of Plaque Psoriasis.局部他卡西醇治疗斑块状银屑病的研究进展。
Ann Pharmacother. 2024 Jan;58(1):76-85. doi: 10.1177/10600280231164775. Epub 2023 Apr 19.
6
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial.罗氟司特乳膏治疗累及面部/颈部及间擦部位的慢性斑块状银屑病的疗效和安全性:一项随机对照试验的事后分析
Br J Dermatol. 2023 May 24;188(6):810-812. doi: 10.1093/bjd/ljad060.
7
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study.罗氟司特乳膏 0.15%和 0.05%治疗特应性皮炎患者的安全性和疗效:随机、双盲、2 期概念验证研究。
J Drugs Dermatol. 2023 Feb 1;22(2):139-147. doi: 10.36849/JDD.7295.
8
A Review of Topical Roflumilast for the Treatment of Plaque Psoriasis.外用罗氟司特治疗斑块状银屑病的综述
Ann Pharmacother. 2023 Aug;57(8):966-969. doi: 10.1177/10600280221137750. Epub 2022 Nov 24.
9
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.罗氟司特乳膏与赋形剂乳膏治疗慢性斑块状银屑病的效果:DERMIS-1 和 DERMIS-2 随机临床试验。
JAMA. 2022 Sep 20;328(11):1073-1084. doi: 10.1001/jama.2022.15632.
10
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial.他卡西醇乳膏治疗斑块状银屑病 1 年的安全性和疗效:PSOARING 3 试验结果。
J Am Acad Dermatol. 2022 Oct;87(4):800-806. doi: 10.1016/j.jaad.2022.06.1171. Epub 2022 Jun 27.